Table 3.

Reported cases and outcomes of rtuximab treatment in established pregnancy

			Pregnancy outcomes
Maternal conditions	Treatment	Time of treatment	Outcomes	Terms (weeks)	Birth weights	Neonatal complications	Ref.
DLCBL	Rituximab + CHOP	21 weeks	Healthy	35	n.a.	Low B cell counts	[102]
Follicular B cell lymphoma	Rituximab	1st trimester	Healthy	40	3·6 kg	n.r.	[103]
AIHA	Rituximab	7–10 weeks	Healthy	38	3·1 kg	n.r.	[104]
DLCBL	Rituximab + CHOP	15 weeks	Healthy	33	Normal range	Low B cell counts	[105]
Burkitt lymphoma	Rituximab + CHOP	16 weeks	Healthy	41	3·8 kg	High level of rituximab at birth	106
TTP	Rituximab	27 weeks	Premature	31	1·04 kg	Intensive care but normal development	[107]
ITP	Rituximab + steroid	30 weeks	Healthy	38	3·8 kg	Low B cell counts	[108]
NHL	Rituximab + CHOP	18 weeks	Healthy	33	2·5 kg	Low B cell counts	[109]
ITP	Rituximab	26 weeks	Healthy	n.s.	n.s.	Low B cell counts	[110]
Atopic dermatitis	Rituximab	1st trimester	Healthy Twins	36	n.a.	n.r.	[111]

AIHA: autoimmune haemolytic anaemia; CHOP: cyclophosphamide, hyroxydaurubicin (doxorubicin), oncovin (vinscristine), and prednisone; DLBL: diffuse large cell B lymphoma; ITP: idiopathic thrombocytopenic purpura; NHL: non-Hodgkin's lymphoma; TTP: thrombotic thrombocytopenic purpura; weeks, weeks of gestation; n.a.: data not available; n.r.: none reported.